Back to Baseline: Erectile Function Recovery After Radical Prostatectomy from the Patients' Perspective
Overview
Reproductive Medicine
Urology
Affiliations
Introduction: A variety of erectile function recovery (EFR) rates are reported post-radical prostatectomy (RP), with some suggesting EFR rates over 90% [1]. Clinical experience suggests that patients view EFR as getting back to their baseline (BTB) erectile functioning (EF) without the use of medication.
Aim: This study explores EFR defined as BTB.
Method: Men pre-RP and 24 months post-RP completed the Erectile Function Domain (EFD) of the International Index of Erectile Function and one question on phosphodiesterase type 5 inhibitor (PDE5i) use. Men using a PDE5i at baseline were excluded.
Main Outcome Measures: At 24 m, "back to baseline" was defined as achieving the baseline EFD score (within 1 point or higher). Analyses included descriptive statistics, chi-square, and logistic regression.
Results: One hundred eighty men had an average age at RP of 59 (SD = 7) years. When including men who were using a PDE5i at 24 months, 43% (N = 78, 95% CI: 36-51%) returned BTB. When considering BTB without the use of a PDE5i, 22% (N = 39, 95% CI: 16% to 28%) returned BTB. When focusing on a subset of men with baseline EFD ≥ 24 (N = 132), 36% (N = 47, 95% CI: 28% to 44%) returned BTB at 24 months using a PDE5i and 16% (N = 21, 95% CI: 11% to 23%) without the use of a PDE5i. For this group, there was a significant difference by age (<60 years, 23% vs. ≥ 60 years, 4%, P < 0.001), which remained a significant predictor (OR = 6.25, 95% CI: 1.88 to 50, P < 0.001) in multivariable analysis.
Conclusions: Twenty-two percent of the entire sample and 16% of the men with functional (EFD ≥ 24) baseline erections returned to BTB EF without the use of medication. Only 4% of men who were ≥ 60 years old with functional erections pre-surgery achieved BTB EF. Although gaining partial EF is also important, men pre-RP should be educated on EFR and the chance of "back to baseline" EF.
Cn T, Il C, Mj H, Mpj N, Ham V, Pj V Support Care Cancer. 2024; 32(11):738.
PMID: 39432123 DOI: 10.1007/s00520-024-08936-y.
Rosser B, Kohli N, Bates A, Talley K, Wright M, Polter E J Cancer Surviv. 2024; .
PMID: 39266938 DOI: 10.1007/s11764-024-01672-6.
Dilixiati D, Kadier K, Lu J, Xie S, Azhati B, Xilifu R Sex Med. 2024; 12(1):qfae002.
PMID: 38348104 PMC: 10859556. DOI: 10.1093/sexmed/qfae002.
Male infertility and urological tumors: Pathogenesis and therapeutical implications.
Gulino G, Distante A, Akhundov A, Bassi P Urologia. 2023; 90(4):622-630.
PMID: 37491831 PMC: 10623618. DOI: 10.1177/03915603221146147.
Salter C, Tin A, Bernie H, Nascimento B, Katz D, Benfante N J Sex Med. 2022; 19(12):1790-1796.
PMID: 36192298 PMC: 10168542. DOI: 10.1016/j.jsxm.2022.08.193.